Newsroom

LONDON--(BUSINESS WIRE)--  Re: SANTANDER UK plc EUR 750,000,000.00 MATURING: 24-Mar-2028 ISIN: XS3032031257 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 24-Jun-2026 TO 24-Sep-2026 HAS BEEN FIXED AT 2.91 PCT DAY BASIS: ACTUAL/360 INTEREST PAYABLE VALUE 24-Sep-2026 WILL AMOUNT TO: EUR 5,583,250.00 PER EUR 750,000,000.00 DENOMINATION  ...

ZUG, Switzerland & VADUZ, Liechtenstein--(BUSINESS WIRE)--After more than a decade as Switzerland's crypto pioneer, the Bitcoin Suisse Group ("Bitcoin Suisse") is expanding across Europe. Its European entity, Bitcoin Suisse (Europe) AG, founded in 2018, has been granted a license as a Crypto Asset Service Provider (CASP) under MiCAR by the Liechtenstein Financial Market Authority (FMA), building on its long-standing registration under the Token and TT Service Provider Act (TVTG). Across Europe,...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: SAMSON ROCK CAPITAL LLP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named....

CAMBRIDGE, England--(BUSINESS WIRE)--TRIMTECH Therapeutics (TRIMTECH or the Company), a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced it has raised an additional $14 million in seed funding, bringing the total for the round to $47 million (£35 million). The financing was led by Johnson & Johnson’s corporate venture capital organization, Johnson & Johnson Innovation –...

BARCELONA, Spain--(BUSINESS WIRE)--eDreams ODIGEO (the “Company” or “eDO”) (BME: EDR) (OTC: EDDRF) the world’s leading travel subscription company, today provided an operational update on the international expansion of its subscription platform, Prime, across Latin America.Following its established multi-year market expansion strategy, the Company is successfully scaling its travel subscription model across the Latin American region, reinforcing the operational foundations required to achieve it...

LONDON--(BUSINESS WIRE)--  Re: Municipality Finance Plc EUR 50,000,000.00 MATURING: 24-Mar-2027 ISIN: XS1579297638 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 24-Jun-2026 TO 24-Sep-2026 HAS BEEN FIXED AT 1.50 PCT DAY BASIS: ACTUAL/360 INTEREST PAYABLE VALUE 24-Sep-2026 WILL AMOUNT TO: EUR 161,000.00 PER EUR 42,000,000.00 DENOMINATION  ...

LONDON--(BUSINESS WIRE)--  Re: SANDWELL COMMERCIAL FINANCE NO.2 PLC GBP 14,000,000.00 MATURING: 30-Sep-2037 ISIN: XS0229031280 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 31-Mar-2026 TO 30-Jun-2026 HAS BEEN FIXED AT 9.00 PCT DAY BASIS: ACTUAL/365(PROP) INTEREST PAYABLE VALUE 30-Jun-2026 WILL AMOUNT TO: GBP 750.02 PER GBP 33,412.11 DENOMINATION  ...

LONDON--(BUSINESS WIRE)--  Re: SANDWELL COMMERCIAL FINANCE NO.2 PLC GBP 21,700,000.00 MATURING: 30-Sep-2037 ISIN: XS0229031017 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 31-Mar-2026 TO 30-Jun-2026 HAS BEEN FIXED AT 6.15 PCT DAY BASIS: ACTUAL/365(PROP) INTEREST PAYABLE VALUE 30-Jun-2026 WILL AMOUNT TO: GBP 512.61 PER GBP 33,412.11 DENOMINATION  ...

KIRKLAND, Quebec & SHANGHAI--(BUSINESS WIRE)--Organon Canada et Shanghai Henlius Biotech, Inc. (2696.HK) ont annoncé aujourd’hui que BILDYOS® (injection de dénosumab) 60 mg/1 mL et TUZEMTY® (injection de dénosumab) 120 mg/1,7 mL, des biosimilaires de PROLIA et de XGEVA, respectivement, sont maintenant disponibles au Canada pour toutes les indications des produits de référence. Utilisés dans plusieurs indications, les produits à base de dénosumab sont indiqués dans le traitement de l’ostéoporose...

KIRKLAND, Quebec & SHANGHAI--(BUSINESS WIRE)--Organon Canada and Henlius expand access to denosumab treatments with launch of BILDYOS® and TUZEMTY® biosimilars to PROLIA and XGEVA...